Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.52 |
| ▸ | GRM3 | Q14832 | 5/20 | 0.52 |
| ▸ | GRM6 | O15303 | 3/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 3/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6693393 | 0.75 | GRM2 (0.50) | GRM2GRM3GRM6GRM8SLC1A2 | |
| SCHEMBL6693397 | 0.75 | GRM2 (0.50) | GRM2GRM3GRM6GRM8SLC1A2 | |
| SCHEMBL6702212 | 0.75 | GRM2 (0.50) | GRM2GRM3GRM6GRM8SLC1A2 | |
| SCHEMBL23718843 | 0.75 | SLC1A2 (0.57) | GRM2GRM3GRM6GRM8SLC1A2 | |
| SCHEMBL6695863 | 0.72 | GRM2 (0.47) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Hydrochloric Acid SCHEMBL5841578 | 0.72 | GRM2 (0.47) | GRM2GRM3GRM6GRM8SLC1A2 | |
| SCHEMBL5840776 | 0.72 | SLC1A2 (0.48) | GRM2GRM3GRM6GRM8SLC1A2 | |
| Hydrochloric Acid SCHEMBL4810986 | 0.72 | SLC1A2 (0.66) | GRM2GRM3GRM6GRM8SLC1A2 | |
| SCHEMBL5842175 | 0.72 | ALDH1A1 (0.38) | — | |
| SCHEMBL5847018 | 0.72 | ALDH1A1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7038077-B2 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| US-20050009912-A1 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY | 2005-01-13 | — | — | US | disclosed |
| US-20040138304-A1 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009912-A1 | Prodrugs of excitatory amino acids | SLC1A2, SLC1A3, SLC1A1 | GRM2 19/4885GRM3 15/4885GRM6 39/4885 |
| US-20040138304-A1 | Prodrugs of excitatory amino acids | SLC1A2, SLC1A1, SLC1A3 | GRM2 22/4885GRM3 25/4885GRM6 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.